CPP (Cancer Prevention Pharmaceuticals) Total Assets : $9.19 Mil (As of Mar. 2016)

View and export this data going back to 2016. Start your Free Trial

What is Cancer Prevention Pharmaceuticals Total Assets?

Cancer Prevention Pharmaceuticals's Total Assets for the quarter that ended in Mar. 2016 was $9.19 Mil.

Total Assets is connected with ROA %. Cancer Prevention Pharmaceuticals's annualized ROA % for the quarter that ended in Mar. 2016 was -240.82%. Total Assets is also linked to Revenue through Asset Turnover. Cancer Prevention Pharmaceuticals's Asset Turnover for the quarter that ended in Mar. 2016 was 0.19.

Cancer Prevention Pharmaceuticals Total Assets Historical Data

The historical data trend for Cancer Prevention Pharmaceuticals's Total Assets can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Cancer Prevention Pharmaceuticals Total Assets Chart

Cancer Prevention Pharmaceuticals Annual Data

Trend

Dec13

Dec14

Dec15

Total Assets

2.00

4.86

1.85

Cancer Prevention Pharmaceuticals Quarterly Data
	Dec13	Dec14	Mar15	Sep15	Dec15	Mar16
Total Assets	Get a 7-Day Free Trial			4.86	-	3.16	1.85	9.19

Cancer Prevention Pharmaceuticals Total Assets Calculation

Total Assets are all the assets a company owns.

From the capital sources of the assets, some of the assets are funded through shareholder's paid in capital and retained earnings of the business. Others are funded through borrowed money.

Cancer Prevention Pharmaceuticals's Total Assets for the fiscal year that ended in Dec. 2015 is calculated as

Total Assets	=	Total Equity (A: Dec. 2015 )	+	Total Liabilities (A: Dec. 2015 )
	=	-21.182	+	23.032
	=	1.85

Cancer Prevention Pharmaceuticals's Total Assets for the quarter that ended in Mar. 2016 is calculated as

Total Assets	=	Total Equity (Q: Mar. 2016 )	+	Total Liabilities (Q: Mar. 2016 )
	=	-22.85	+	32.039
	=	9.19

Cancer Prevention Pharmaceuticals (AMEX:CPP) Total Assets Explanation

Total Assets is connected with ROA %.

Cancer Prevention Pharmaceuticals's annualized ROA % for the quarter that ended in Mar. 2016 is

ROA %	=	Net Income (Q: Mar. 2016 )	/	( (Total Assets (Q: Dec. 2015 )	+	Total Assets (Q: Mar. 2016 ))	/ count )
	=	-13.292	/	( (1.85	+	9.189)	/ 2 )
	=	-13.292	/	5.5195
	=	-240.82 %

Note: The Net Income data used here is four times the quarterly (Mar. 2016) data.

In the article Joining The Dark Side: Pirates, Spies and Short Sellers, James Montier reported that In their US sample covering the period 1968-2003, Cooper et al find that firms with low asset growth outperformed firms with high asset growth by an astounding 20% p.a. equally weighted. Even when controlling for market, size and style, low asset growth firms outperformed high asset growth firms by 13% p.a. Therefore a company with fast asset growth may underperform.

Total Assets is linked to total revenue through Asset Turnover.

Cancer Prevention Pharmaceuticals's Asset Turnover for the quarter that ended in Mar. 2016 is

	Asset Turnover
=	Revenue (Q: Mar. 2016 )	/	( (Total Assets (Q: Dec. 2015 )	+	Total Assets (Q: Mar. 2016 ))	/ count )
=	1.038	/	( (1.85	+	9.189)	/ 2 )
=	1.038	/	5.5195
=	0.19

Therefore, if a company grows its Total Assets faster than its Revenue, the Asset Turnover will decline. This might be a warning sign for the business.

Cancer Prevention Pharmaceuticals Total Assets Related Terms

Thank you for viewing the detailed overview of Cancer Prevention Pharmaceuticals's Total Assets provided by GuruFocus.com. Please click on the following links to see related term pages.

Cancer Prevention Pharmaceuticals Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Cancer Prevention Pharmaceuticals Inc (AMEX:CPP) » Definitions » Total Assets

Comparable Companies

Traded in Other Exchanges

N/A

Address

Website

http://www.canprevent.com

Cancer Prevention Pharmaceuticals Inc is a pharmaceutical company. It was originally incorporated under the laws of the state of Arizona on June 9, 2008, as Cancer Prevention Pharmaceuticals, LLC and on December 22, 2009, Cancer Prevention Pharmaceuticals, Inc. was incorporated in the state of Delaware. The Company currently operates mainly in the development and commercialization of compound CPP-1X, otherwise known as DFMO or eflornithine. It is involved in familial adenomatous polyposis, neuroblastoma and the prevention of recurrence in colon cancer survivors. However, CPP also has therapeutic prevention approaches for prostate cancer, breast cancer, and skin cancers which will be developed together with the National Cancer Institute (as resources become available in the future) and multiple academic partners. Its competitors are Marina Biotech, Inc., SLA Pharma AG, StemSynergy Therapeutics, Inc. and Thetis Pharmaceuticals LLC. The Company holds license to approximately six issued patents in the United States. The Company's activities are subject to risks and uncertainties including failure to obtain required regulatory approvals to market the products, once developed, in the USA or foreign markets.